drugset
drugset / Trial / NCT06993844

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844 ↗

Phase 1/2 Recruiting 233 enrolled Ensem Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

Timeline

Start
2025-06-10
Primary completion
2027-06-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ETX-636 Unknown — Oral
Background Fulvestrant Small molecule 500 mg Other

Indications

breast cancer